Abstract:Neuroblastoma is one of the most common types of pediatric cancer. In current neuroblastoma prognosis, patients can be stratified into high- and low-risk groups. Generally, more than 90% of the patients in the low-risk group will survive, while less than 50% for those with the high-risk disease will survive. Since the so-called “high-risk” patients still contain patients with mixed good and poor outcomes, more refined stratification needs to be established so that for the patients with poor outcome, they can receive prompt and individualized treatment to improve their long-term survival rate, while the patients with good outcome can avoid unnecessary over treatment. We first mined co-expressed gene modules from microarray and RNA-seq data of neuroblastoma samples using the weighted network mining algorithm lmQCM, and summarize the resulted modules into eigengenes. Then patient similarity weight matrix was constructed with module eigengenes using two different approaches. At the last step, a consensus clustering method called Molecular Regularized Consensus Patient Stratification (MRCPS) was applied to aggregate both clinical information (clinical stage and clinical risk level) and multiple eigengene data for refined patient stratification. The integrative method MRCPS demonstrated superior performance to clinical staging or transcriptomic features alone for the NB cohort stratification. It successfully identified the worst prognosis group from the clinical high-risk group, with less than 40% survived in the first 50 months of diagnosis. It also identified highly differentially expressed genes between best prognosis group and worst prognosis group, which can be potential gene biomarkers for clinical testing. To address the need for better prognosis and facilitate personalized treatment on neuroblastoma, we modified the recently developed bioinformatics workflow MRCPS for refined patient prognosis. It integrates clinical information and molecular features such as gene co-expression for prognosis. This clustering workflow is flexible, allowing the integration of both categorical and numerical data. The results demonstrate the power of survival prognosis with this integrative analysis workflow, with superior prognostic performance to only using transcriptomic data or clinical staging/risk information alone. This article was reviewed by Lan Hu, Haibo Liu, Julie Zhu and Aleksandra Gruca.

Recent advances in molecular genetic characterization of high-risk neuroblastoma

Clinical and pathological analysis of the olfactory neuroblastoma

Research frontiers and reflections on neuroblastoma

A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.

Molecular Basis and Clinical Features of Neuroblastoma

Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors

Research advances of MYCN and ALK gene-related targeted drugs in the treatment of neuroblastoma

Pathogenesis, Biomarkers and Therapeutic Targets

Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes

Recent advances in pediatric hereditary neoplastic syndromes

Advancing therapy for neuroblastoma

Recent progress of molecular pathology for bone tumors

Genomic Analysis-Integrated Whole-Exome Sequencing of Neuroblastomas Identifies Genetic Mutations in Axon Guidance Pathway

Molecular Biological Study on Glioma in Post-genomic Era

Research therapeutic advances of oncolytic virus for neuroblastoma

Research status and development trends of omics in neuroblastoma a bibliometric and visualization analysis

Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma

An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs

Identification of the molecular subtypes and construction of risk models in neuroblastoma

Recent Advances in the Molecular Classification of Gliomas Based on Gene and Protein Expression Profiles

Integration of Molecular Features with Clinical Information for Predicting Outcomes for Neuroblastoma Patients